ALFA Finder| Revenue growth | 36% YoY Q4 growth; full year FY26 remained largely flat. |
|---|---|
| Margins | 34.3% EBITDA margin in Q4; long-term sustainable range 26-28%. |
| Demand visibility | Low in Europe due to war; improving pilot-to-commercial transitions. |
| Management confidence | Balanced; emphasized deliberate groundwork over aggressive top-line expansion. |
Growth
Q4 revenue grew 36% YoY and 56% QoQ; EBITDA surged 69% sequentially due to better product mix.
Outlook
Block 7 commercial production starts Q2 FY27; CRAMS expected to drive visible outcomes throughout FY27.
Risks
Global geopolitical volatility and prolonged regulatory approvals in Europe/Japan delay commercialization of high-margin CRAMS projects.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹624.30
- Market cap
- ₹801.5 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 66.2×Sector 43.8×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Shree Ganesh Remedies Results Update
Shree Ganesh Remedies released a press release on Q2 and H1 FY27 unaudited results, with Q2 revenue of ₹23.29 Crore, down 23% year-on-year. PAT fell 67% to ₹1.63 Crore.
Shree Ganesh Remedies Q2 FY27 Results: Net Profit ₹1.6 Cr, Down 68.0% YoY
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
- Key figure
- Net profit ₹1.6 Cr · -68.0% YoY
Shree Ganesh Remedies Board Meeting Date
Shree Ganesh Remedies Ltd notified BSE of a board meeting on October 31, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 2026. Trading window remains closed until 48 hours after the results declaration.
Shree Ganesh Remedies Other Announcement
Shree Ganesh Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Shree Ganesh Remedies Management Change
Shree Ganesh Remedies Ltd has announced the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and the appointment of Ms. Akanksha as his successor.